BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Sandoz GmbH submitted on  1 July 2004 an application for Marketing Authorisation to 
the European Medicines Agency (EMEA) for Omnitrope, through the centralised procedure under the 
legal base of Similar Biological Medicinal Product referring to Article 10.4 of Directive 2004/27/EC. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
Dr Frits Lekkerkerker         
Co-Rapporteur: 
Dr Harald Enzmann 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on  1 July 2004.  The legal base for the application 
was Similar Biological Medicinal Product referring to Article 10.4 of Directive 2004/27/EC. 
The procedure started on 16 August 2004. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
29 October 2004.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 26 October 2004. 
During  the  meeting  on  13-16  December  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 16 December 2004. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
4 February 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 24 March 2005. 
During  the  CHMP  meeting  on  18-21  April  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 20 May 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the list 
of outstanding issues to all CHMP members on 9 June 2005. 
The BWP during its meeting of 13-15 June 2005 adopted the BWP Report to be transmitted to 
the CHMP for endorsement. 
During  the  CHMP  meeting  on  20-23  June  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues  (Following  assessment  of  responses  to  Day  180  List  of  Outstanding  Issues)  to  be 
addressed in writing by the applicant. 
The applicant submitted the responses to the CHMP list of outstanding issues on 1 July 2005. 
The BWP during its meeting of 18-20 July 2005 adopted the BWP Report to be transmitted to 
the CHMP for endorsement. 
During  the  CHMP  meeting  on  25-28  July  2005,  the  CHMP  discussed  the  responses  to  the 
outstanding issues.  
During  the  CHMP  meetings  of  September,  November  and  December  2005,  updates  were 
provided with regard to the responses to the outstanding issues. 
During January 2006, the outstanding issues were clarified in a satisfactory manner. 
The applicant submitted a revised Letter of Undertaking, 23 January 2006. 
During the meeting on 23-26 January 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Omnitrope on 26 January 2006. 
1/1 
ª EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
